Abstract
A quantitative structure-activity relationship (QSAR) study has been made on a novel series of substituted 3-[3-(aminopropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-1,3-dihydro-indole-2-ones as potent inhibitors of the non-receptor Src tyrosine kinase. The activity is found to be significantly correlated with calculated hydrophobicity and molar refractivity of the molecule. The correlation obtained suggests that the activity of the compounds is controlled by the hydrophobic and steric properties of the molecules. The internal and external validation of the correlation is judged by calculating r2cv (= 0.66) for the training set and r2pred (= 0.52) for test set. Using the correlation, some new compounds have been predicted possessing higher potencies than the compounds in the existing series.
Keywords: Quantitative structure-activity relationship, Src tyrosine kinase inhibitors, Tyrosine kinase inhibitors, QSAR, hydrophobicity, tyrosine kinase, transmembrane receptor-linked kinase, RTKs, tetrahydroindole, aminopropyl, calculated molar refractivity (CMR), ClogP, R1-substituents, Protease Inhibitors, Integrase Inhibitors
Letters in Drug Design & Discovery
Title: A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Volume: 8 Issue: 10
Author(s): Zaihra Anwer and Satya P. Gupta
Affiliation:
Keywords: Quantitative structure-activity relationship, Src tyrosine kinase inhibitors, Tyrosine kinase inhibitors, QSAR, hydrophobicity, tyrosine kinase, transmembrane receptor-linked kinase, RTKs, tetrahydroindole, aminopropyl, calculated molar refractivity (CMR), ClogP, R1-substituents, Protease Inhibitors, Integrase Inhibitors
Abstract: A quantitative structure-activity relationship (QSAR) study has been made on a novel series of substituted 3-[3-(aminopropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-1,3-dihydro-indole-2-ones as potent inhibitors of the non-receptor Src tyrosine kinase. The activity is found to be significantly correlated with calculated hydrophobicity and molar refractivity of the molecule. The correlation obtained suggests that the activity of the compounds is controlled by the hydrophobic and steric properties of the molecules. The internal and external validation of the correlation is judged by calculating r2cv (= 0.66) for the training set and r2pred (= 0.52) for test set. Using the correlation, some new compounds have been predicted possessing higher potencies than the compounds in the existing series.
Export Options
About this article
Cite this article as:
Anwer Zaihra and P. Gupta Satya, A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors, Letters in Drug Design & Discovery 2011; 8 (10) . https://dx.doi.org/10.2174/157018011797655250
DOI https://dx.doi.org/10.2174/157018011797655250 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Aptamer-Based Strategies for Stem Cell Research
Mini-Reviews in Medicinal Chemistry Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis
Current Topics in Medicinal Chemistry The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Structural and Functional Organization of miRNAs
Current Pharmacogenomics Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Biomedical Applications of Carbon Nanotubes: A Critical Review
Current Drug Delivery Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design 3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas
Current Medicinal Chemistry